Overview

A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of NIC5-15 in the treatment of Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Humanetics Corporation
Collaborators:
James J. Peters Veterans Affairs Medical Center
National Center for Complementary and Integrative Health (NCCIH)